Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2014, Vol. 8 Issue (3) : 368-375     DOI: 10.1007/s11684-014-0360-0
RESEARCH ARTICLE |
Effects of comprehensive therapy based on traditional Chinese medicine patterns on older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomized, controlled study
Minghang Wang1,3,Jiansheng Li2,3,*(),Suyun Li1,3,Yang Xie1,3
1. Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
2. The Geriatric Department, Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China
3. Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment and Chinese Medicine Development of Henan Province, Zhengzhou 450046, China
Download: PDF(202 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  

This study aimed to evaluate the efficacy of comprehensive therapy based on traditional Chinese medicine (TCM) patterns on older patients with chronic obstructive pulmonary disease (COPD) through a four-center, open-label, randomized controlled trial. Patients were divided into the trial group treated using conventional western medicine and Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen granules, and Yi-Qi Zi-Shen granules based on TCM patterns respectively; and the control group treated using conventional western medicine. A total of 136 patients≥65 years completed the study, with 63 patients comprising the trial group and 73 comprising the control group. After the six-month treatment and the 12-month follow-up period, significant differences were observed between the trial and control groups in the following aspects: frequency of acute exacerbation (P≤0.040), duration of acute exacerbation (P = 0.034), symptoms (P≤0.034), 6-min walking distance (6MWD) (P≤0.039), dyspnea scale (P≤0.036); physical domain (P≤0.019), psychological domain (P≤0.033), social domain (P≤0.020), and environmental domain (P≤0.044) of the WHOQOL-BREF questionnaire; and daily living ability domain (P≤0.007), social activity domain (P≤0.018), depression symptoms domain (P≤0.025), and anxiety symptoms domain (P≤0.037) of the COPD-QOL. No differences were observed between the trial and control groups with regard to FVC, FEV1, and FEV1%.

Keywords chronic obstructive pulmonary disease      older adult      clinical trial      Bu-Fei Jian-Pi granules      Bu-Fei Yi-Shen granules      Yi-Qi Zi-Shen granules     
Corresponding Authors: Jiansheng Li   
Online First Date: 09 September 2014    Issue Date: 09 October 2014
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-014-0360-0     OR     http://academic.hep.com.cn/fmd/EN/Y2014/V8/I3/368
Fig.1  Enrollment of patients and completion of the subgroup analysis.
CharacteristicsTrial group (n= 63)Control group (n= 73)t/χ2/ZP
Age (year)72.48±3.9171.92±3.890.8330.406
Course of disease?222.75±455.50182.92±130.730.7140.476
BMI?23.16±10.7922.55±3.540.6340.478
Exacerbation
Frequency (times)3.10±2.043.05±2.030.1160.908
Duration (day)10.67±7.1710.64±6.480.0200.984
Lung function
FVC (L)2.83±0.992.78±0.970.2870.775
FEV1 (L)1.32±0.501.34±0.49-0.1560.876
FEV1%47.60±10.6849.95±13.81-1.0930.276
Gender
Male49653.1640.075
Female148
Smoking status
Currently smoking41562.2370.135
Not smoking2217
Number of packs smoked per month21.49±12.1519.78±11.020.7180.475
GOLD classification
GOLD 145
GOLD 223310.5780.749
GOLD 33637
Tab.1  Baseline characteristics of the patients
VariableTrial group (n = 63)Control group (n = 73)t/χ2/ZP
Frequency (times)
?Month 03.10±2.043.05±2.030.1160.908
?Month 60.46±0.590.73±0.85-2.0770.040
?Month 180.94±0.981.45±1.71-3.8330.000
?Average frequency0.62±0.651.18±0.97-3.9410.000
Frequency (constituent ratio)
?With exacerbation3760
?Without exacerbation26139.1010.003
Duration (days)
?Average duration4.08±5.526.62±4.80-2.5230.034
Tab.2  Comparison of the frequency and duration of AECOPD
Fig.2  Change in and comparison of the results of FVC, FEV1, FEV1%, total scores of symptoms, dyspnea scale, and 6MWD.
Fig.3  Change in quality of life and comparison of the physical, psychological, environmental, social domain, and total scores of the WHOQOL-BREF questionnaire and that of the results of COPD-QOL for daily living ability, social activity, depression symptoms, anxiety symptoms domain, and total scores at baseline for months 3, 6, and 18.
1 Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med2014; 35(1): 7–16
doi: 10.1016/j.ccm.2013.10.002 pmid: 24507833
2 World Health Organization. World Health Statistics2013. Available in: http://www.who.int/gho/publications/world_health_statistics/2013/en/
3 Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis2012; 7: 457–494
doi: 10.2147/COPD.S32330 pmid: 22927753
4 Kaplan A, Hernandez P, O’Donnell D. Less smoke, more fire: what’s new for you in the latest COPD guidelines? Can Fam Physician2008; 54(5): 737–739
pmid: 18474708
5 Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults—United States, 2011. Morb Mortal Wkly Rep 2012; 61(46): 938–943
pmid: 23169314
6 China National Committee on Ageing. China’s Aged Population to More than Double by 2053. http://en.cncaprc.gov.cn/Policies/47033.jhtml
7 Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, Liu S, Wang X, Wang D, Lu J, Zheng J, Ran P. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med2007; 176(8): 753–760
doi: 10.1164/rccm.200612-1749OC pmid: 17575095
8 Gelberg J, McIvor RA. Overcoming gaps in the management of chronic obstructive pulmonary disease in older patients: new insights. Drugs Aging2010; 27(5): 367–375
doi: 10.2165/11535220-000000000-00000 pmid: 20450235
9 Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med2011; 155(3): 179–191
doi: 10.7326/0003-4819-155-3-201108020-00008 pmid: 21810710
10 Hanania NA, Sharma G, Sharafkhaneh A. COPD in the elderly patient. Semin Respir Crit Care Med2010; 31(5): 596–606
doi: 10.1055/s-0030-1265900 pmid: 20941660
11 Li JS, Li SY, Wang ZW, Yu XQ, Wang MH, Wang YY. TCM Diagnosis and treatment guidelines for chronic obstructive pulmonary disease (2011 Edition). J Tradit Chin Med (Zhong Yi Za Zhi)2012; 53: 80–84 (in Chinese)
12 Li SY, Li JS, Wang MH, Xie Y, Yu XQ, Sun ZK, Ma LJ, Zhang W, Zhang HL, Cao F, Pan YC. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study. BMC Complement Altern Med2012; 12(1): 197
doi: 10.1186/1472-6882-12-197 pmid: 23107470
13 Li JS, Li SY, Yu XQ, Xie Y, Wang MH, Li ZG, Zhang NZ, Shao SJ, Zhang YJ, Zhu L, Guo LX, Bai YP, Wang YF. Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study. J Ethnopharmacol2012; 141(2): 584–591
doi: 10.1016/j.jep.2011.08.060 pmid: 21911051
14 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Revised2006). http://goldcopd.com/index.2007-01-22
15 COPD Study Group of Chinese Society of Respiratory Disease. Treatment guidelines of Chronic Obstructive Pulmonary Disease (Revised 2007). Chin J Tuberc Respir Dis (Zhonghua Jie He He Hu Xi Za Zhi)2007; 30(1): 8–17 (in Chinese)
16 Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21(41): 46–53
doi: 10.1183/09031936.03.00078002 pmid: 12795331
17 Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J2004; 23(6): 932–946
doi: 10.1183/09031936.04.00014304 pmid: 15219010
18 Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest1988; 93(3): 580–586
doi: 10.1378/chest.93.3.580 pmid: 3342669
19 WHO. The World Health Organization Quality of Life (WHOQOL-BREF). Geneva: World Health Organization. 2004
20 Cai YY, Li ZZ, Fang ZJ. The evaluation of the quality of life of chronic obstructive pulmonary disease. Chin J Gen Pract (Zhonghua Quan Ke Yi Shi)2004; 3(4): 225–227 (in Chinese)
21 Pistelli R, Ferrara L, Misuraca C, Bustacchini S. Practical management problems of stable chronic obstructive pulmonary disease in the elderly. Curr Opin Pulm Med2011; 17(Suppl 1): S43–S48
doi: 10.1097/01.mcp.0000410747.20958.39 pmid: 22209930
22 Blanchette CM, Berry SR, Lane SJ. Advances in chronic obstructive pulmonary disease among older adults. Curr Opin Pulm Med2011; 17(2): 84–89
doi: 10.1097/MCP.0b013e32834316ff pmid: 21178625
23 Gooneratne NS, Patel NP, Corcoran A. Chronic obstructive pulmonary disease diagnosis and management in older adults. J Am Geriatr Soc2010; 58(6): 1153–1162
doi: 10.1111/j.1532-5415.2010.02875.x pmid: 20936735
24 Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients’ health status following early identification of a COPD exacerbation. Eur Respir J2007; 30(5): 907–913
doi: 10.1183/09031936.00166606 pmid: 17715163
25 Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet2007; 370(9589): 786–796
doi: 10.1016/S0140-6736(07)61382-8 pmid: 17765528
26 Bellia V, Sorino C, Catalano F, Augugliaro G, Scichilone N, Pistelli R, Pedone C, Antonelli-Incalzi R. Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax2008; 63(1): 60–66
doi: 10.1136/thx.2007.080572 pmid: 17702791
27 Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med2000; 343(26): 1902–1909
doi: 10.1056/NEJM200012283432601 pmid: 11136260
28 Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med2008; 359(15): 1543–1554
doi: 10.1056/NEJMoa0805800 pmid: 18836213
29 Camargo LA, Pereira CA. Dyspnea in COPD: beyond the modified Medical Research Council scale. J Bras Pneumol2010; 36(5): 571–578
pmid: 21085822
30 Morales-Blanhir JE, Palafox Vidal CD, Rosas Romero MJ, García Castro MM, Londo?o Villegas A, Zamboni M. Six-minute walk test: a valuable tool for assessing pulmonary impairment. J Bras Pneumol2011; 37(1): 110–117
doi: 10.1590/S1806-37132011000100016 pmid: 21390439
31 Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil2010; 91(2): 221–225
doi: 10.1016/j.apmr.2009.10.017 pmid: 20159125
32 Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, Wang C, Bourbeau J. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med2008; 178(9): 913–920
doi: 10.1164/rccm.200804-619OC pmid: 18755925
33 Al Aqqad S, Hyder Ali IA, Md Kassim RM, Sarriff A, Tangiisuran B. Evaluation of the characteristics, anxiety, and depression among older patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Chest2014; 145(Suppl 3): 393A
doi: 10.1378/chest.1823747
34 Li JS, Li SY, Wang MH. Functional status and living quality change of chronic obstructive pulmonary diseases. J Henan Univ Chin Med (Henan Zhong Yi Xue Yuan Xue Bao)2007; 22(1): 19–22 (in Chinese)
[1] Shuyang Sun,Zhiyuan Zhang. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization[J]. Front. Med., 2016, 10(1): 104-110.
[2] Xu Chen, Xiaomao Xu, Fei Xiao. Heterogeneity of chronic obstructive pulmonary disease: from phenotype to genotype[J]. Front Med, 2013, 7(4): 425-432.
[3] Sowmya Viswanathan, Armand Keating. Overcoming the challenges of conducting translational research in cell therapy[J]. Front Med, 2011, 5(4): 333-335.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed